{"prompt": "['Carbomer and Carboxymethylcellulose', '209510', 'Clinical Protocol V1.0', 'A diary will be supplied to promote compliance and to capture details of product use throughout', 'the study period. Subjects may also record additional information such as AEs or medications', 'used. Any additional details relevant to efficacy or safety should be reviewed by the investigator', '(or suitably qualified designee) with the subjects, and transcribed to the CRF as appropriate.', 'The number of any missed or additional applications or doses will be captured as protocol', 'deviations and transcribed from the diary into the CRF. Subjects will be re-instructed in the', 'correct usage requirements and diary completion as needed.', '6.8', 'Concomitant Medication/Treatment(s)', 'Any medications, treatments or vaccine (including over-the-counter or prescription medicines,', 'vitamins, and/or herbal supplements) taken during the study, from signing the informed consent,', 'must be recorded in the CRF with indication, reason for use, unit dose, daily dose, and start and', 'stop dates of administration. All subjects will be questioned about concomitant medication/', 'treatments at each site visit.', 'Details of any relevant dental, medical or surgical history (within the last year), including', 'allergies or drug sensitivity, will be recorded in the CRF. The use of concomitant medications', 'is permitted in this study except for the use of bisphosphonate drugs and any medications that', 'in the opinion of the investigator would interfere with the conduct of this study per the inclusion/', 'exclusion criteria.', 'Medication/treatments taken within 7 days prior to signing the informed consent form will be', 'documented as a prior medication/treatment. Medications/treatments taken after signing the', 'informed consent form will be documented as concomitant medication/treatments.', '7', 'DISCONTINUATION OF STUDY INTERVENTION AND', 'SUBJECT DISCONTINUATION/WITHDRAWAL', '7.1', 'Subject Discontinuation/Withdrawal', 'A subject may withdraw from the study at any time at his or her own request, or may be', 'withdrawn at any time at the discretion of the investigator or Sponsor for safety, behavioral', 'reasons, or the inability of the subject to comply with the protocol-required schedule of study', 'visits or procedures.', 'The following circumstances require discontinuation of study product and/or premature subject', 'withdrawal:', \"Protocol violation that may impact the subject's safety\", 'Withdrawal of informed consent', 'Subject lost to follow-up', 'Unblinding of the subject', 'Pregnancy', 'If a subject is discontinued or prematurely withdraws from the study, the reason(s) for', 'discontinuation or withdrawal and the associated date must be documented in the relevant', 'section(s) of the CRF.', '7.2', 'Lost to Follow up', 'A subject will be considered lost to follow up if he or she repeatedly fails to return for scheduled', 'visits and is unable to be contacted by the study site.', 'GlaxoSmithKline Consumer Healthcare Confidential', 'Template Version Effective: 18-May-18 (CCR #11475)', 'Page 26 of 65']['Carbomer and Carboxymethylcellulose', '209510', 'Clinical Protocol V1.0', 'If a subject fails to return to the site for a required study visit the site must attempt to contact', 'the subject and reschedule the missed visit as soon as possible and counsel the subject on the', 'importance of maintaining the assigned visit schedule and ascertain whether or not the subject', 'wishes to and/or should continue in the study.', 'Before a subject is deemed lost to follow up, the investigator or designee must make every effort', 'to regain contact with the subject (where possible, 3 telephone calls and, if necessary, a certified', \"letter to the subject's last known mailing address or local equivalent methods). These contact\", 'attempts should be documented. If contact is made with the subject, the investigator should', 'inquire about the reason for withdrawal, request that the subject return all products that they', 'had been dispensed and if appropriate request that the subject return for a final visit, and', 'follow-up with the subject regarding any unresolved AEs.', 'Final safety assessments may be carried out when the subject returns to the study site, at the', \"investigator's discretion, which could include an OST (edentulous) examination.\", 'Should the subject continue to be unreachable, he/she will be considered to have withdrawn', 'from the study and lost to follow up.', 'Lack of completion of all or any of the early termination procedures will not be viewed as', \"protocol deviations so long as the subject's safety was preserved.\", 'If the subject withdraws from the study and also withdraws consent for disclosure of future', 'information, no further evaluations should be performed and no additional data should be', 'collected. The Sponsor may retain and continue to use any data collected before such', 'withdrawal of consent.', '8', 'STUDY PROCEDURES', 'This section lists the procedures to be completed at each planned study visit. The timing of', 'each procedure is listed in the Schedule of Activities section.', 'Adherence to the study design requirements, including all procedures are essential and required', 'for study conduct.', '8.1', 'Visit 1/Screening', 'Screening procedures will be conducted by the Investigator, or suitably qualified designee.', 'Subjects will be screened prior to administration of the investigational product to confirm that', 'they meet the subject selection criteria for the study.', 'The following Screening procedures will be completed, in the following order (wherever', 'possible), and the findings recorded in the CRF:', 'Informed Consent', 'Inclusion/Exclusion Criteria', 'Demographics', 'Medical History and Prior Medication/Treatment', 'Dental History', 'Clean Dentures', 'Well-Made Assessment of Dentures', 'Denture Bearing Tissue Score', 'GlaxoSmithKline Consumer Healthcare Confidential', 'Template Version Effective: 18-May-18 (CCR #11475)', 'Page 27 of 65']\n\n###\n\n", "completion": "END"}